Vanguard Personalized Indexing Management
ABCL icon

Vanguard Personalized Indexing Management’s AbCellera Biologics ABCL Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Buy
16,261
+2,273
+16% +$11.1K ﹤0.01% 2007
2026
Q1 		$48.8K Buy
13,988
+1,110
+9% +$3.99K ﹤0.01% 2057
2025
Q4 		$44K Buy
12,878
+176
+1% +$786 ﹤0.01% 1896
2025
Q3 		$63.9K Buy
12,702
+234
+2% +$1.03K ﹤0.01% 1880
2025
Q2 		$42.8K Buy
12,468
+1,146
+10% +$2.85K ﹤0.01% 1848
2025
Q1 		$25.2K Sell
11,322
-11,055
-49% -$31.7K ﹤0.01% 1749
2024
Q4 		$65.6K Buy
22,377
+7,426
+50% +$20.7K ﹤0.01% 1667
2024
Q3 		$38.9K Buy
14,951
+1,024
+7% +$2.84K ﹤0.01% 1700
2024
Q2 		$41.2K Buy
13,927
+621
+5% +$2.35K ﹤0.01% 1602
2024
Q1 		$60.3K Sell
13,306
-953
-7% -$4.86K ﹤0.01% 1556
2023
Q4 		$81.4K Buy
+14,259
New +$66.1K ﹤0.01% 1490

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Vanguard Personalized Indexing Management's ABCL Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its AbCellera Biologics (ABCL) stake by 16% in Q2 2026, buying an estimated $11.1K and bringing the position to 16,261 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

Vanguard Personalized Indexing Management first reported a position in ABCL in Q4 2023 and has held it in 11 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Vanguard Personalized Indexing Management held 16,261 shares of AbCellera Biologics worth $128K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 2,273 AbCellera Biologics shares in Q2 2026, an estimated $11.1K.
  • AbCellera Biologics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2007 holding.
  • Vanguard Personalized Indexing Management first reported a position in AbCellera Biologics in Q4 2023 and has held it in 11 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.